Camp4 Therapeutics (CAMP) EBITDA Margin (2023 - 2026)
Camp4 Therapeutics (CAMP) posted EBITDA Margin of 1010.12% for Q1 2026, up 72.49% sequentially from 3671.26% in Q4 2025, and up 51668.0% YoY from N/an in Q1 2025.
Camp4 Therapeutics (CAMP) EBITDA Margin (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 1010.12% in Q1 2026.
- Quarterly EBITDA Margin rose 51668.0% year-over-year to 1010.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1335.18% (up 219542.0% YoY) and the FY2025 annual result came in at 1502.43%, up 663990.0% from the prior year.
- EBITDA Margin advanced to 1010.12% in Q1 2026 per CAMP's latest filing, from 3671.26% in the prior quarter.
- Over five years, EBITDA Margin peaked at 870.27% in Q2 2025 and troughed at 3671.26% in Q4 2025.
- A 4-year average of 2067.6% and a median of 1717.11% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin tumbled 151881 bps in 2025, then jumped 51668 bps in 2026.
- Over 4 years, EBITDA Margin stood at 3525.14% in 2023, then soared by 39 bps to 2152.45% in 2024, then tumbled by 71 bps to 3671.26% in 2025, then jumped by 72 bps to 1010.12% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1010.12%, 3671.26%, and 1717.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - | -752.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -752.11% |
| Mar 31, 2026 | -1,010.12% |
| Dec 31, 2025 | -3,671.26% |
| Sep 30, 2025 | -1,717.11% |
| Jun 30, 2025 | -870.27% |
| Mar 31, 2025 | -1,526.81% |
| Dec 31, 2024 | -2,152.45% |
| Sep 30, 2023 | -3,525.14% |